Patrick Arbuthnot to DNA, Circular
This is a "connection" page, showing publications Patrick Arbuthnot has written about DNA, Circular.
Connection Strength
2,976
-
Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus. Virus Res. 2018 01 15; 244:311-320.
Score: 0,554
-
A T7 Endonuclease I Assay to Detect Talen-Mediated Targeted Mutation of HBV cccDNA. Methods Mol Biol. 2017; 1540:85-95.
Score: 0,554
-
Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus. Mol Ther. 2016 Apr; 24(4):671-7.
Score: 0,522
-
Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol Ther. 2013 Oct; 21(10):1889-97.
Score: 0,436
-
Hepatitis B virus: promising drug targets and therapeutic implications. Expert Opin Ther Targets. 2021 06; 25(6):451-466.
Score: 0,186
-
Advances with RNAi-Based Therapy for Hepatitis B Virus Infection. Viruses. 2020 08 04; 12(8).
Score: 0,177
-
Inhibition of replication of hepatitis B virus using transcriptional repressors that target the viral DNA. BMC Infect Dis. 2019 Sep 12; 19(1):802.
Score: 0,167
-
A convenient method to generate and maintain poly(A)-encoding DNA sequences required for in vitro transcription of mRNA. Biotechniques. 2019 01; 66(1):37-39.
Score: 0,159
-
Differing prospects for the future of using gene therapy to treat infections with hepatitis B virus and hepatitis C virus. Discov Med. 2015 Sep; 20(109):137-43.
Score: 0,126
-
Improved Specificity and Safety of Anti-Hepatitis B Virus TALENs Using Obligate Heterodimeric FokI Nuclease Domains. Viruses. 2021 07 12; 13(7).
Score: 0,047
-
Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approach. World J Gastroenterol. 2021 Jun 21; 27(23):3182-3207.
Score: 0,047